Thyroid cancer incidence trends by histology in 25 countries: a population-based study
Thyroid cancer incidence trends by histology in 25 countries: a population-based study
复制标题
DOI：
10.1016/s2213-8587(21)00027-9
复制
发表时间：
2021-03-16
影响因子：
44.5
通讯作者：
Dal Maso, Luigino
中科院分区：
文献类型：
--
作者：
Miranda-Filho, Adalberto;Lortet-Tieulent, Joannie;Dal Maso, Luigino
背景在过去的30年里，甲状腺癌的发病率在世界范围内的不同人群中有所增加。我们在这里概述了甲状腺癌发病率的主要组织学亚型的国际趋势。方法采用国际癌症研究机构（IARC）收集的1998-2012年期间甲状腺癌发病率数据进行了一项基于人群的研究。数据摘自《五大洲癌症发病率加纲要》。我们选择了25个国家的数据，这些国家的癌症登记人口超过200万人（总共87个登记）。进一步的标准是，选定的登记区域的未指明甲状腺癌比例必须小于10%，分析仅限于20-84岁的个体。我们计算了年龄在20 - 84岁之间的个体的年龄特异性发病率和年龄标准化发病率每10万人年，并根据1998-2002年和2008- 2012年年龄标准化发病率的绝对变化，评估了国家、性别和主要组织学亚型（乳头状、滤泡状、髓样或间变性）的趋势。在所有研究国家中，乳头状甲状腺癌是总体甲状腺癌的主要诱因，并且是所有国家中唯一系统性增加的组织学亚型，尽管各国之间存在很大差异。在女性中，2008- 2012年期间，年龄标准化的甲状腺乳头状癌发病率在荷兰、英国和丹麦为每10万人年4.3-5.3例，在韩国为每10万人年143.3例。在同一时期，男性乳头状甲状腺癌的年龄标准化发病率从泰国的每10万人1.2例到韩国的每10万人30.7例不等。在亚洲许多国家，2000年以后妇女甲状腺乳头状癌发病率的增加特别明显；自2009年左右以来，美国、奥地利、克罗地亚、德国、斯洛文尼亚、西班牙、立陶宛和保加利亚的离婚率趋于稳定。滤泡性甲状腺癌和髓样甲状腺癌的时间趋势在各国之间没有一致的模式，但在1998-2002年和2008- 2012年期间，25个国家中有21个国家的间变性甲状腺癌略有下降。2008- 2012年，滤泡亚型的年龄标准化发病率为每10万名女性0.5至2.5例（每10万名男性0.3至1.5例），而髓样亚型的发病率为每10万名女性或男性不到1例，间变性甲状腺癌的发病率为每10万名女性或男性不到0.2例。在1998年至2012年期间，甲状腺癌发病率的快速增长仅发生在乳头状甲状腺癌中，该亚型更有可能以亚临床形式发现，因此需要对甲状腺进行严格检查。版权所有(C) 2021世界卫生组织。Elsevier Ltd.出版。版权所有。
Background The incidence of thyroid cancer has increased in different populations worldwide in the past 30 years. We present here an overview of international trends of thyroid cancer incidence by major histological subtypes.Methods We did a population-based study with data for thyroid cancer incidence collected by the International Agency for Research on Cancer (IARC) for the period 1998-2012. Data were extracted from the Cancer Incidence in Five Continents plus compendium. We selected data for 25 countries that had a population of more than 2 million individuals covered by cancer registration (87 registries in total). Further criteria were that the selected registration areas had to have a proportion of unspecified thyroid cancer of less than 10% and analyses were restricted to individuals aged 20-84 years. We calculated age-specific incidence rates and age-standardised rates per 100 000 person-years for individuals aged 20 to 84 years, and assessed trends by country, sex, and major histological subtype (papillary, follicular, medullary, or anaplastic) based on absolute changes in age-standardised incidence rates between 1998-2002 and 2008-12.Findings Papillary thyroid cancer was the main contributor to overall thyroid cancer in all the studied countries, and was the only histological subtype that increased systematically in all countries, although with large variability between countries. In women, the age-standardised incidence rate of papillary thyroid cancer during 2008-12 ranged from 4.3-5.3 cases per 100 000 person-years in the Netherlands, the UK, and Denmark, to 143.3 cases per 100 000 women in South Korea. For men during the same period, the age-standardised incidence rates of papillary thyroid cancer per 100 000 person-years ranged from 1.2 cases per 100 000 in Thailand to 30.7 cases per 100 000 in South Korea. In many countries in Asia, the increase in papillary thyroid cancer rates in women was particularly pronounced after the year 2000; rates stabilised since around 2009 in the USA, Austria, Croatia, Germany, Slovenia, Spain, Lithuania, and Bulgaria. Temporal trends for follicular and medullary thyroid cancer did not show consistent patterns across countries, but slight decreases were seen for anaplastic thyroid cancer in 21 of 25 countries between 1998-2002, and 2008-12. In 2008-12, age-standardised rates for the follicular subtype ranged between 0.5 and 2.5 cases per 100 000 women (and between 0.3 and 1.5 per 100 000 men), while those for the medullary subtype were always less than 1 case per 100 000 women or men, and for anaplastic thyroid cancer less than 0.2 cases per 100 000 women or men.Interpretation In the period from 1998 to 2012, the rapid increases in thyroid cancer incidence were observed only for papillary thyroid cancer, the subtype more likely to be found in a subclinical form and therefore detected by intense scrutiny of the thyroid gland. Copyright (C) 2021 World Health Organization. Published by Elsevier Ltd. All rights reserved.